About Sree...

              Dr. Sreejith Raveendran graduated with his Ph.D in Bionanoscience with an emphasis on cancer drug delivery and nanomedicine from Toyo University, Japan in 2013. After acquiring his doctoral degree from Bio Nano Electronics Research centre, he was pursuing his nanoresearch in Cancer nanotechnology and targeted nanotherapy through the MSCA-IF and postdoctoral research position at The United Kingdom and Japan respectively. Dr. Raveendran focuses on the novel combinatorial approaches in immunochemo therapies of cancer and infectious diseases via bio-nanotechnological platforms. He synthesizes & characterizes novel nanoparticle formulations with multiple functional moieties, chemotherapeutic agents and imaging modalities that specifically binds to the target proteins in cancer cells. He studies the cellular and molecular mechanisms behind the nanoparticle toxicity, drug activity and immunological stimulations after specific targeting through new multimodal therapeutics. His expertise is not limited to nanotechnology but microbiology, immunology, cancer biology, tissue engineering, material science, molecular biology, bioengineering and microscopy. He worked as Research Associate in Infection pharmacology at AstraZeneca India Pvt. Ltd., and Junior Research Associate in Abl Biotechnologies Ltd., India, during his early career. He worked as Project Coordinator at Nanoscale Research Facility, Indian Institute of Technology, Delhi under Joint Bio Nano Research mission (Phase II) during the period 2019 - 2022. Presently, he is working as Assistant Professor/Lecturer in Biotechnology at School of Health and Life Sciences, Teesside University, Middlesbrough and Group leader in Nanomedicine & Combination therapeutics at National Horizon Centre, Darlington, UK.

​

​

​

​

• Feb 2022- Till date: Assistant Professor/Lecturer in Biotechnology at School of Health and Life Sciences, Teesside University, Middlesbrough and Group leader in Nanomedicine & Combination therapeutics at National Horizon Centre, Darlington, UK.,
   

• Nov 2019- Jan 2022: Project coordinator, Collaborative education and research program between Nanoscale Research Facility, IIT-Delhi and Bionano Electronics Research Centre, Toyo University, Japan under Joint Bio Nano Mission Program (Phase II).

​

• Oct 2017- Oct 2019: Marie Sklodowska Curie Actions Individual Fellow, Received H2020-MSCA-IF-749403, GLIOMA, University of Brighton, Brighton, United Kingdom for development of glioma nanovaccine and anticancer drug delivery.

​

• Apr 2013- Sept 2017: Postdoctoral research fellow at Bionano Electronics Research Centre, Toyo University, Japan under Programme for the Strategic Research Foundation at Private Universities, S1101017, MEXT, Japan.

​

• Apr 2010- March 2013: Pursued Docotral studies in Bionanoscience fusion and acquired Ph.D in Lifesciences from BNERC, Toyo University, Japan.

​

• Sept 2009- March 2010: Research Associate at Infection Pharmacology, Astrazeneca Pharmaceuticals Limited, Bangalore, India. conducted drug discovery research and high- throughput screening of drug candidates against Mycobacterium tuberculosis.

​

• Feb 2008- Aug 2009: Junior Research Associate at Bioresources Division, ABL Biotechnologies Limited, Chennai, India.

​

• July 2005- April 2007: Completed Master of Science in Microbiology (M.Sc. Microbiology) and secured Univeristy First rank and gold medal from J.J. College of Arts & Science, Pudukkottai, Tamil Nadu, India (Affiliated to Bharathidasan University).

​

• July 2005- April 2006: Completed Post Graduate Diploma in Bioinformatics (PGDBI) from J.J. College of Arts & Science, Pudukkottai, Tamil Nadu, India (Affiliated to Bharathidasan University).

​

• July 2002- April 2005: Completed Bachelor of Science in Microbiology (B.Sc. Microbiology) from Sree Narayana Guru College of Arts & Science, Coimabatore, Tamil Nadu, India (Affiliated to Bharathiar University)

​

​

​

​

• Cancer immunotherapy using targeted nanoparticles & vaccine development

• Cell biology & Immunology; Molecular pathway analysis; Gene & protein studies.

• Advanced Bioimaging: Light & Electron Microscopy, 3D visualization.

• Novel aspects of nanodrug delivery & aptamer targeting.

• Molecular & cellular mechanisms behind cancers & infectious diseases

• Cancer biology, medical immunology & In vivo toxicological studies.

• Tissue engineering, 3D Bio-printing, regenerative medicine, electrospinning.

• Nanofabrication of biosensors

• Application of novel biocompatible polymers & extremophilic microbiology.

• Development of nanoparticles for immuno-drug targeting & multimodal imaging.

​

​

​

• Pharmidex Pharmaceutical Services, London Collaboration: GLIOMA project, funded by H2020 as a part of MSCA- IF, was partly performed at PPS, Hatfield, London. Pharmidex as a pharmaceutical service provider includes all significant facilities required for drug discovery research. The nano formulation produced at University of Brighton was tested for DMPK, in vitro cytotoxicity, in vivo studies and LCMS analysis at PPS. Glioma, GL261 sub-cutaneous tumor model using C57BL/6 mice were developed for the present project and growth kinetics of the tumor was studied at PPS. Pharmacokinetics studies for the nanoformulations was tested for drug release and gold accumulation in C57BL/6 mice models.

 

• Thermo scientific, FEI, Japan Collaboration: This project involved Tokyo Nano port facility, Shinagawa, Japan and Shanghai Nano port facility, China in collaboration with Toyo University. The potential and feasibility of applying FIB-SEM for the 3D dynamic rendering of therapeutic nanocage interaction with multiple sub-cellular organelles after targeted drug delivery to breast cancer cells was studied and evaluated. Excellent results were obtained and 3D rendering soft wares like AMIRA was used to generate segmented 3D dynamic videos and images. Apart from that 3D EDS mapping of the constitutive elements were performed for gold nanocages embedded inside subcellular organelles of breast cancer cells. Most sophisticated TEM (TALOS FX200) and FIB-SEM (Helios) were used for this study. Manuscripts with excellent research results are in preparation for communication with high impact peer- reviewed journals.

 

• JEOL Japan Ltd. Collaboration: Investigated multiple killing mechanisms in breast cancer cells by dual-targeted gold nanocages using SBF-SEM and TEM- Tomography. Resin embedded breast cancer samples treated with dual- targeted nanocages was used for the experiments. 3D rendering of the cellular organelles interacting with gold nanocages were performed using several soft wares like TEMography, Colorist, UCSF Chimera, FIJI, ImageJ, etc. in collaboration with expert application scientists from JEOL Japan Ltd.  Three manuscripts with ground-breaking research results are in the communication stage and one research article has already published in Nano Research, 2016, 10 (3), 1078-1091 entitled, Ultra-fast microwave aided synthesis of gold nanocages and structural maneuver studies.

 

• AstraZeneca India Pvt. Ltd.: Sreejith joined AstraZeneca as a Research Associate in microbiology at the Department of Infection pharmacology involved in high throughput screening of tuberculosis drug candidates and screening of tuberculosis mutants. Period spent during tuberculosis research developed an innate passion within, to solve several mysteries in infectious diseases.

 

• ABL Biotechnologies Ltd.: He worked in ABL Biotechnologies ltd., in Chennai as Junior research associate in biotechnology and biopharmaceutical research. Liposome-based drug delivery applications and production and extraction of pharmaceutically active ingredients from fungi, algae and cyanobacteria were major projects dealt.

​

​